Innate Pharma Files 6-K Report
Ticker: IPHA · Form: 6-K · Filed: Apr 13, 2026
Sentiment: neutral
Topics: regulatory-filing, foreign-issuer
TL;DR
Innate Pharma dropped a 6-K on 4/13/26. Standard update filing.
AI Summary
Innate Pharma SA filed a 6-K report on April 13, 2026. The filing includes a 6-K document and an exhibit (EX-99.1). The company's mailing and business address is 117 Avenue de Luminy, Marseille, France.
Why It Matters
This filing provides an update on Innate Pharma's regulatory activities and corporate information, which is important for investors tracking the company's compliance and operational status.
Risk Assessment
Risk Level: low — This is a routine foreign issuer report (6-K) and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Filer of the 6-K report
- 0001598599 (company) — CIK number for Innate Pharma SA
- 2026-04-13 (date) — Filing date and period of report
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that provides certain information which the issuer makes or is required to make public pursuant to the laws of the issuer's home country or jurisdiction of incorporation or organization, or to which it makes or is required to make public by home country regulatory authorities or stock exchanges.
What are the accession number and filing date for this specific 6-K?
The SEC Accession No. is 0001628280-26-024819 and the Filing Date is 2026-04-13.
Where is Innate Pharma SA located?
Innate Pharma SA's mailing and business address is 117 Avenue de Luminy, BP 30191, Marseille, France.
What is the CIK number for Innate Pharma SA?
The CIK number for Innate Pharma SA is 0001598599.
What type of business is Innate Pharma SA primarily involved in, according to the SIC code?
According to the SIC code (2836), Innate Pharma SA is primarily involved in Biological Products, excluding Diagnostic Substances.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 13, 2026 regarding Innate Pharma SA (IPHA).